Skip to main content

Table 3 Multivariate analysis

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 PFSOS
MultivariateMultivariate
HR95% CIp valueHR95% CIp value
ECOG
 0 or 1  0.003  < 0.001
 2 or 31.9071.245–2.921 2.6071.666–4.080 
Diagnosis   
 NSCLC  0.062   
 Othersa1.3280.986–1.788    
Stage
 III  0.025  0.103
 IV2.6051.130–6.004 2.3320.842–6.461 
Number of metastatic organ
 0 or 1     0.007
 ≥ 2   1.61.135–2.256 
Number of treatment line
 1st  < 0.001   
 2nd2.0351.410–2.939< 0.001   
 ≥ 3rd1.8851.269–2.8000.002   
Clinical trial
 Yes     0.001
 No   1.8291.266–2.641 
Antibiotics during ICI
 No  0.037   
 Yes0.70.501–0.978    
Antibiotics before ICI
 No  0.001  0.001
 Yes1.7151.264–2.326 1.7851.265–2.519 
  1. aMelanoma, Bladder cancer, Renal cell carcinoma, Head and Neck cancer, Stomach cancer, Hepato cellular carcinoma, Esophageal cancer, Small cell lung cancer, Anal cancer, Cervical cancer, Colorectal cancer, Jejunal cancer, MUO, Ovarian cancer, Sarcoma